We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study.
- Authors
David G. Maggs; Mark Fineman; Jonathan Kornstein; Terrie Burrell; Sherwyn Schwartz; Yan Wang; James A. Ruggles; Orville G. Kolterman; Christian Weyer
- Abstract
To assess the postprandial glucose-lowering effect of the human amylin analog pramlintide when given with insulin lispro in subjects with type 2 diabetes, with an emphasis on the optimal dose timing relative to meals. In this randomized, single-blind, placebo-controlled, five-way crossover study, 19 subjects with type 2 diabetes using insulin lispro underwent five consecutive mixed-meal tests. In randomized order, subjects received subcutaneous injections of placebo at -15 min or 120-µg pramlintide at -15, 0, +15, or +30 min relative to the standardized breakfast after an overnight fast. Insulin lispro was injected at 0 min at doses that were adjusted appropriately for both the content of the standardized meal and the anticipated effects of pramlintide. Plasma glucose concentrations were measured before and during the 4-h postmeal period. When injected at 0 min, pramlintide reduced the postprandial glucose excursion by 81% compared to insulin lispro + placebo (incremental AUC04 h (mean ± SE) 2.0 ± 1.5 vs. 10.4 ± 2.2 mmol/h/L, P < 0.05). When pramlintide was injected at -15, +15, and +30 min, the postprandial incremental glucose AUC04 h was also significantly reduced (P < 0.05), but to a lesser extent (42 to 73%). Pramlintide treatment was well tolerated and no serious adverse events were reported. Administration of pramlintide either at or just prior to a meal caused a greater reduction in postprandial glucose than either administration of placebo or postmeal pramlintide injections in subjects with type 2 diabetes treated with a rapid-acting insulin analog, insulin lispro. Copyright © 2004 John Wiley & Sons, Ltd.
- Subjects
GLUCOSE; INSULIN; DIABETES; DOSE-response relationship in biochemistry; AMYLIN
- Publication
Diabetes/Metabolism Research & Reviews, 2004, Vol 20, Issue 1, p55
- ISSN
1520-7552
- Publication type
Article
- DOI
10.1002/dmrr.419